Spruce Biosciences, Inc. Board of Directors

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

Dr. Kirk Ways M.D., Ph.D.

Dr. Kirk Ways M.D., Ph.D.

Interim Chief Medical Officer & Director

Ms. P. J. Ramtin

Ms. P. J. Ramtin

Senior Vice President of Business Operations

Mr. Michael G. Grey

Mr. Michael G. Grey

Executive Chairman

Ms. Heidi Petersen M.P.H.

Ms. Heidi Petersen M.P.H.

Senior Vice President of Regulatory & Quality

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.